Moreover, beyond the currently used donepezil, galantamine, and rivastigmine, research is anticipated on pharmacotherapeutic targets that possess AChE-inhibiting properties and could improve gait and reduce falls in patients with neurodegenerative diseases, thereby enhancing cholinergic function [41, 42]. This evidence concerns the gene ACHE and neurodegenerative disease.